Ethos Technologies Inc. (LIFE)
NASDAQ (CM) NASDAQ (CM) Primary 
XSTU Summary
Ethos Technologies Inc. (LIFE) Presents at Goldman Sachs Communacopia + Technology Conference 2026 Transcript
Ethos Technologies Inc. (LIFE) Presents at Goldman Sachs Communacopia + Technology Conference 2026 Transcript
Ethos Technologies: The Cheapest Growth Story In Its Peer Group
Ethos trades at 22x FY2026 non-GAAP EPS, but guidance has risen 42% since its January IPO, making the multiple look less demanding than it first appears. LIFE carries the lowest PEG ratio in its peer group despite growing revenue several times faster than any direct comparable. Ethos raised a $100 million buyback alongside its August guidance increase, a confident capital allocation signal just seven months after going public.
Ethos Technologies Inc. (LIFE) Q2 2026 Earnings Call Transcript
Ethos Technologies Inc. (LIFE) Q2 2026 Earnings Call Transcript
Ethos Technologies Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Robin Blackmon Aflac Inc | 8,901 | $99,424.17 | $350,321.11 | $250,896.94 | 252.35% |
| NA Nizar Araji National Bank Of Canada /FI/ | 81 | $904.77 | $2,560.41 | $1,655.64 | 182.99% |
| MT Michael Taylor Board of Trustees of The Leland Stanford Junior University | 31,940 | $356,770 | $1.07M | $711,623 | 199.46% |
 Kimberly Cappellano Private Wealth Asset Management LLC | 5,263 | $58,788 | $206,178.02 | $147,390.02 | 250.71% |
 Jennifer Grunberg Allspring Global Investments Holdings LLC | 261,373 | $2.92M | $10.23M | $7.31M | 250.31% |
Ethos Technologies Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Ross Sandler Barclays | 527.39 | $17,941.76 | $20,947.88 | $3,006.12 | 16.75% |
Ethos Technologies Inc. (LIFE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ethos Technologies Inc. ever had a stock split?
Ethos Technologies Inc. Profile
| Biotechnology Industry | Healthcare Sector | Peter George Colis CEO | NASDAQ (CM) Exchange | 29765A101 CUSIP |
| US Country | 614 Employees | - Last Dividend | 1 Jul 2019 Last Split | 7 May 2015 IPO Date |
Overview
aTyr Pharma, Inc. is a pioneering biotherapeutics company focused on the discovery and development of innovative medicines derived from novel immunological pathways. With a strong foundation in scientific research and a dedicated pursuit of groundbreaking treatments, aTyr Pharma is at the forefront of addressing unmet medical needs. Founded in 2005 and based in the heart of biotech innovation, San Diego, California, the company has positioned itself as a leader in harnessing immunological pathways to combat various diseases. Through its commitment to innovation and patient care, aTyr Pharma aims to unlock new possibilities in medicine and improve the lives of patients suffering from serious illnesses.
Products and Services
efzofitimod
As the leading therapeutic candidate of aTyr Pharma, efzofitimod is a forefront innovation in the treatment of pulmonary sarcoidosis and other interstitial lung diseases (ILDs). This selective modulator of NRP2 is currently under rigorous evaluation in a Phase III clinical trial specifically for pulmonary sarcoidosis, showcasing its potential as a pioneering treatment option. Furthermore, efzofitimod is exploring its versatility in a Phase 1b/2a clinical trial targeting a spectrum of ILDs, including chronic hypersensitivity pneumonitis and connective tissue disease-related ILD, underscoring aTyr Pharma’s dedication to expanding the therapeutic applications of its products.
ATYR0101
Emerging from aTyr Pharma’s innovative pipeline is ATYR0101, a fusion protein that originates from a domain of aspartyl-tRNA synthetase. This promising candidate is in the preclinical development stage for the treatment of fibrosis, demonstrating aTyr Pharma’s commitment to leveraging its unique understanding of immunological pathways to address this challenging medical condition.
ATYR0750
Another notable development from aTyr Pharma is ATYR0750, a protein derived from a domain of alanyl-tRNA synthetase aimed at treating liver disorders. This candidate is at the forefront of addressing liver conditions, further emphasizing the company’s broad expertise in targeting complex diseases through novel biological mechanisms.
In addition to its impressive portfolio of innovative therapeutics, aTyr Pharma has entered into a strategic collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. This partnership focuses on the development and commercialization of efzofitimod for ILDs in Japan, highlighting aTyr Pharma’s commitment to global healthcare solutions through synergistic collaborations.
